Bordetella T Cell Epitope Megapools for Precise Immune Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for optimized antigens and T cell epitopes for Bordetella, particularly B. pertussis, to enhance diagnostics, treatments, and vaccines, as well as for detecting and characterizing specific responses to Bordetella infections and post-vaccination states.
Innovation Solution
Compositions comprising specific Bordetella T cell epitopes, including peptides and proteins, are developed, which can be formulated with adjuvants and used in immunogenic formulations to stimulate and enhance T cell responses, and methods for detecting Bordetella-specific T cells through peptide-MHC interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional Bordetella diagnostics and vaccines are used, then basic immune response detection is possible, but detection precision and characterization accuracy of B. pertussis specific responses are insufficient
Solution Approach 1:
The patent segments the Bordetella antigen into multiple discrete T cell epitope peptides (2598 distinct peptides across Tables 1-20). This segmentation allows for precise detection of specific epitope-specific T cell responses, enabling high measurement precision in diagnosing B. pertussis infections and characterizing post-vaccination states while maintaining manageable complexity through systematic organization of the peptide set.
2Reliability
If comprehensive Bordetella antigen coverage is provided, then diagnostic accuracy is improved, but the complexity of the diagnostic system increases
Solution Approach 1:
The patent creates a universal T cell epitope peptide set that serves multiple diagnostic functions: detecting B. pertussis infections, characterizing post-vaccination states, and identifying epitope-specific T cell responses. This multi-functional peptide library (2598 peptides covering Tables 1-20) improves diagnostic reliability across different clinical scenarios while maintaining a standardized system that can be implemented through common ELISPOT or flow cytometry assays.
3Quantity of substance
If traditional vaccine antigens are used, then basic vaccination is achieved, but the ability to stimulate and enhance T cell responses is insufficient
Solution Approach 1:
The patent formulates composite peptide compositions combining multiple Bordetella T cell epitope peptides (from Tables 1-20) with adjuvants. This composite approach creates enhanced immunogenic formulations that stimulate robust T cell responses (increasing quantity of T cell activation) while using established adjuvant technologies to manage formulation complexity. The composite nature allows synergistic effects between multiple epitopes and adjuvant components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively stimulate and enhance T cell responses, enabling accurate detection and characterization of Bordetella infections and post-vaccination states, and provide protective immune responses against Bordetella infections.
Implementation Method 1
methods for detecting Bordetella-specific T cells through peptide-MHC interactions
Implementation Method 2
the one or more peptides or proteins has a length from about 9-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-75 or 75-100 amino acids. In another aspect, the one or more peptides or proteins elicits, stimulates, induces, promotes, increases or enhances a T cell response to a Bordetella
Data Source
AI summary
The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: a Bordetella or an immune response relevant to a Bordetella infection including T cells responsive to one or more Bordetella peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences, fusion proteins, a pool of 2 or more peptides, or polynucleotides that expression the amino acid sequences selected from those set forth in any one of Tables 1-20 (SEQ ID NOS: 1 to 2598). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.